公开(公告)号：US5258284A

公开(公告)日：1993-11-02

申请号：US643303

申请日：1991-01-22

Applicant: J. Glenn Morris, Jr. ,  Anita Wright

Inventor： J. Glenn Morris, Jr. ,  Anita Wright

IPC: C12Q1/68

CPC classification number: C12Q1/689 ,  Y10S435/909

Abstract: Nucleic acid probes specific for pathogenic stains of vibrio vulnificus and methods employing the same, comprising nucleic acid hybridization probes specific for the vvh gene of pathogenic strains of vibrio vulnificus.

Abstract translation: 特异于创伤弧菌的致病性染色体的核酸探针及使用其的方法，其包含特异于创伤弧菌致病菌株的vvh基因的核酸杂交探针。

公开(公告)号：US20130338018A1

公开(公告)日：2013-12-19

申请号：US13521504

申请日：2011-01-13

Applicant: Jianli Dai ,  J. Glenn Morris

Inventor： Jianli Dai ,  J. Glenn Morris

IPC: C12Q1/68

CPC classification number: C12Q1/689 ,  C12Q2600/16

Abstract: The subject invention pertains to an assay and a method for diagnosing, identifying and/or differentiating microorganisms, and in particular bacteria such as Mycobacterium spp. within biological samples. The present invention also relates to assays, gene arrays, probes and primers, nucleic acids and methods for detecting microorganisms in a sample.

Abstract translation: 本发明涉及用于诊断，鉴定和/或分化微生物，特别是细菌如分枝杆菌（Mycobacterium spp）的测定和方法。 在生物样品中。 本发明还涉及用于检测样品中微生物的测定法，基因阵列，探针和引物，核酸和方法。

公开(公告)号：US20130164374A1

公开(公告)日：2013-06-27

申请号：US13772573

申请日：2013-02-21

Applicant: J. Glenn MORRIS ,  Alexander Sulakvelidze ,  Zemphira Alavidze ,  Gary R. Pasternack ,  Torrey C. Brown

Inventor： J. Glenn MORRIS ,  Alexander Sulakvelidze ,  Zemphira Alavidze ,  Gary R. Pasternack ,  Torrey C. Brown

IPC: A61K35/76

CPC classification number: C08L77/12 ,  A01N63/00 ,  A23B4/22 ,  A23B7/155 ,  A23G9/30 ,  A23L3/34635 ,  A23L3/3571 ,  A61K9/7007 ,  A61K35/76 ,  A61K38/164 ,  A61L2/00 ,  A61L2/0005 ,  A61L2/18 ,  A61L2/22 ,  A61L15/225 ,  A61L15/26 ,  A61L15/38 ,  A61L15/44 ,  A61L26/0019 ,  A61L26/0052 ,  A61L26/0066 ,  A61L2300/404 ,  C08G69/44 ,  C12N7/00 ,  C12N2795/00032 ,  C12N2795/00051 ,  Y02A50/473 ,  Y02A50/481

Abstract: The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage.

公开(公告)号：US08003323B2

公开(公告)日：2011-08-23

申请号：US12264582

申请日：2008-11-04

Applicant: J. Glenn Morris ,  Alexander Sulakvelidze ,  Zemphira Alavidze ,  Gary R. Pasternack ,  Torrey C. Brown

Inventor： J. Glenn Morris ,  Alexander Sulakvelidze ,  Zemphira Alavidze ,  Gary R. Pasternack ,  Torrey C. Brown

IPC: C12Q1/68 ,  A61K35/00

CPC classification number: C08L77/12 ,  A01N63/00 ,  A23B4/22 ,  A23B7/155 ,  A23G9/30 ,  A23L3/34635 ,  A23L3/3571 ,  A61K9/7007 ,  A61K35/76 ,  A61K38/164 ,  A61L2/00 ,  A61L2/0005 ,  A61L2/18 ,  A61L2/22 ,  A61L15/225 ,  A61L15/26 ,  A61L15/38 ,  A61L15/44 ,  A61L26/0019 ,  A61L26/0052 ,  A61L26/0066 ,  A61L2300/404 ,  C08G69/44 ,  C12N7/00 ,  C12N2795/00032 ,  C12N2795/00051 ,  Y02A50/473 ,  Y02A50/481

Abstract: The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage.

Abstract translation: 本发明提供了一种通过用含有在病原菌中产生溶解性感染的一种或多种菌株的噬菌体的药物组合物治疗易感患者来降低易感患者细菌感染或败血症风险的方法。 优选地，患者的治疗通过至少一个对数降低对噬菌体敏感的致病细菌的定植水平。 在典型的实施方案中，易感患者是选自白血病患者，淋巴瘤患者，癌症患者，肉瘤患者，同种异体移植患者，先天性或后天免疫缺陷病人，囊性纤维化患者和艾滋病患者的免疫受损患者。 在优选的模式中，通过该方法治疗的患者被所述噬菌体感染的致病细菌定植。

公开(公告)号：US20120148505A1

公开(公告)日：2012-06-14

申请号：US13214579

申请日：2011-08-22

Applicant: J. Glenn Morris ,  Alexander Sulakvelidze ,  Zemphira Alavidze ,  Gary R. Pasternack ,  Torrey C. Brown

Inventor： J. Glenn Morris ,  Alexander Sulakvelidze ,  Zemphira Alavidze ,  Gary R. Pasternack ,  Torrey C. Brown

IPC: A61K35/66 ,  A61K8/99 ,  C12N7/00 ,  A61P31/04

CPC classification number: C08L77/12 ,  A01N63/00 ,  A23B4/22 ,  A23B7/155 ,  A23G9/30 ,  A23L3/34635 ,  A23L3/3571 ,  A61K9/7007 ,  A61K35/76 ,  A61K38/164 ,  A61L2/00 ,  A61L2/0005 ,  A61L2/18 ,  A61L2/22 ,  A61L15/225 ,  A61L15/26 ,  A61L15/38 ,  A61L15/44 ,  A61L26/0019 ,  A61L26/0052 ,  A61L26/0066 ,  A61L2300/404 ,  C08G69/44 ,  C12N7/00 ,  C12N2795/00032 ,  C12N2795/00051 ,  Y02A50/473 ,  Y02A50/481

Abstract: The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage.

Abstract translation: 本发明提供了一种通过用含有在病原菌中产生溶解性感染的一种或多种菌株的噬菌体的药物组合物治疗易感患者来降低易感患者细菌感染或败血症风险的方法。 优选地，患者的治疗通过至少一个对数降低对噬菌体敏感的致病细菌的定植水平。 在典型的实施方案中，易感患者是选自白血病患者，淋巴瘤患者，癌症患者，肉瘤患者，同种异体移植患者，先天性或后天免疫缺陷病人，囊性纤维化患者和艾滋病患者的免疫受损患者。 在优选的模式中，通过该方法治疗的患者被所述噬菌体感染的致病细菌定植。

公开(公告)号：US06699701B1

公开(公告)日：2004-03-02

申请号：US09757687

申请日：2001-01-11

Applicant: Alexander Sulakvelidze ,  J. Glenn Morris, Jr. ,  Zemphira Alavidze ,  Gary R. Pasternack ,  Torrey C. Brown

Inventor： Alexander Sulakvelidze ,  J. Glenn Morris, Jr. ,  Zemphira Alavidze ,  Gary R. Pasternack ,  Torrey C. Brown

IPC: C12N701

CPC classification number: C08L77/12 ,  A01N63/00 ,  A23B4/22 ,  A23B7/155 ,  A23G9/30 ,  A23L3/34635 ,  A23L3/3571 ,  A61K9/7007 ,  A61K35/76 ,  A61K38/164 ,  A61L2/00 ,  A61L2/0005 ,  A61L2/18 ,  A61L2/22 ,  A61L15/225 ,  A61L15/26 ,  A61L15/38 ,  A61L15/44 ,  A61L26/0019 ,  A61L26/0052 ,  A61L26/0066 ,  A61L2300/404 ,  C08G69/44 ,  C12N7/00 ,  C12N2795/00032 ,  C12N2795/00051 ,  Y02A50/473 ,  Y02A50/481

Abstract: Methods and devices for sanitation using bacteriophage are disclosed. According to one embodiment of the present invention, a method for sanitation using at least one bacteriophage includes the steps of (1) storing the at least one bacteriophage in a container; and (2) applying the at least one bacteriophage to a surface to be sanitized with a dispersing mechanism. According to another embodiment of the present invention, a sanitation device that dispenses at least one bacteriophage includes a container, at least one bacteriophage stored in the container, and a dispersing mechanism that disperses the at least one bacteriophage from the container.

公开(公告)号：US06183973B2

公开(公告)日：2001-02-06

申请号：US09205283

申请日：1998-12-04

Applicant: Anita C. Wright ,  Jan L. Powell ,  J. Glenn Morris, Jr.

Inventor： Anita C. Wright ,  Jan L. Powell ,  J. Glenn Morris, Jr.

IPC: G01N3353

CPC classification number: C12Q1/689 ,  C07K14/28

Abstract: The present invention is directed to oligonucleotides used as amplification primers and assay probes for specific and sensitive for virulent strains of V. vulnificus. The target sequence of the probes and primers according to present invention is a capsular polysaccharide (CPS) transport gene (wza) of V. vulnificus. These probes can detect wza DNA or RNA in an unknown sample suspected to have pathogenic strains of V. vulnificus including human, animal, or environmental samples. The invention is also directed to in vitro-expressed protein from the cloned wza for production of polyclonal or monoclonal antibody that is specific for the wza gene product and will detect the V. vulnificus Wza protein in a sample comprising unknown protein.

Abstract translation: 本发明涉及用作扩增引物的寡核苷酸和用于对创伤弧菌的毒性毒株的特异性和敏感性的测定探针。 根据本发明的探针和引物的靶序列是创伤弧菌的荚膜多糖（CPS）转运基因（wza）。 这些探针可以检测怀疑患有包括人，动物或环境样品在内的创伤致病菌株的未知样品中的wza DNA或RNA。 本发明还涉及用于产生对wza基因产物特异性的多克隆或单克隆抗体的克隆wza的体外表达的蛋白质，并且将检测包含未知蛋白质的样品中的创伤弧菌Wza蛋白。

公开(公告)号：US20090053144A1

公开(公告)日：2009-02-26

申请号：US12264582

申请日：2008-11-04

Applicant: J. Glenn MORRIS ,  Alexander Sulakvelidze ,  Zemphira Alavidze ,  Gary R. Pasternack ,  Torrey C. Brown

Inventor： J. Glenn MORRIS ,  Alexander Sulakvelidze ,  Zemphira Alavidze ,  Gary R. Pasternack ,  Torrey C. Brown

IPC: A61K8/99 ,  A61K35/76

CPC classification number: C08L77/12 ,  A01N63/00 ,  A23B4/22 ,  A23B7/155 ,  A23G9/30 ,  A23L3/34635 ,  A23L3/3571 ,  A61K9/7007 ,  A61K35/76 ,  A61K38/164 ,  A61L2/00 ,  A61L2/0005 ,  A61L2/18 ,  A61L2/22 ,  A61L15/225 ,  A61L15/26 ,  A61L15/38 ,  A61L15/44 ,  A61L26/0019 ,  A61L26/0052 ,  A61L26/0066 ,  A61L2300/404 ,  C08G69/44 ,  C12N7/00 ,  C12N2795/00032 ,  C12N2795/00051 ,  Y02A50/473 ,  Y02A50/481

Abstract: The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage.

Abstract translation: 本发明提供了一种通过用含有在病原菌中产生溶解性感染的一种或多种菌株的噬菌体的药物组合物治疗易感患者来降低易感患者细菌感染或败血症风险的方法。 优选地，患者的治疗通过至少一个对数降低对噬菌体敏感的致病细菌的定植水平。 在典型的实施方案中，易感患者是选自白血病患者，淋巴瘤患者，癌症患者，肉瘤患者，同种异体移植患者，先天性或后天免疫缺陷病人，囊性纤维化患者和艾滋病患者的免疫受损患者。 在优选的模式中，通过该方法治疗的患者被所述噬菌体感染的致病细菌定植。

公开(公告)号：US07459272B2

公开(公告)日：2008-12-02

申请号：US10724900

申请日：2003-12-02

Applicant: J. Glenn Morris ,  Alexander Sulakvelidze ,  Zemphira Alavidze ,  Gary R. Pasternack ,  Torrey C. Brown

Inventor： J. Glenn Morris ,  Alexander Sulakvelidze ,  Zemphira Alavidze ,  Gary R. Pasternack ,  Torrey C. Brown

IPC: C12Q1/68 ,  A61K35/00 ,  C12N1/20

CPC classification number: C08L77/12 ,  A01N63/00 ,  A23B4/22 ,  A23B7/155 ,  A23G9/30 ,  A23L3/34635 ,  A23L3/3571 ,  A61K9/7007 ,  A61K35/76 ,  A61K38/164 ,  A61L2/00 ,  A61L2/0005 ,  A61L2/18 ,  A61L2/22 ,  A61L15/225 ,  A61L15/26 ,  A61L15/38 ,  A61L15/44 ,  A61L26/0019 ,  A61L26/0052 ,  A61L26/0066 ,  A61L2300/404 ,  C08G69/44 ,  C12N7/00 ,  C12N2795/00032 ,  C12N2795/00051 ,  Y02A50/473 ,  Y02A50/481

Abstract: The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage.

Abstract translation: 本发明提供了一种通过用含有在病原菌中产生溶解性感染的一种或多种菌株的噬菌体的药物组合物治疗易感患者来降低易感患者细菌感染或败血症风险的方法。 优选地，患者的治疗通过至少一个对数降低对噬菌体敏感的致病细菌的定植水平。 在典型的实施方案中，易感患者是选自白血病患者，淋巴瘤患者，癌症患者，肉瘤患者，同种异体移植患者，先天性或后天免疫缺陷病人，囊性纤维化患者和艾滋病患者的免疫受损患者。 在优选的模式中，通过该方法治疗的患者被所述噬菌体感染的致病细菌定植。

公开(公告)号：US6132710A

公开(公告)日：2000-10-17

申请号：US818995

申请日：1997-03-17

Applicant: Pinaki Panigrahi ,  Ira H. Gewolb ,  J. Glenn Morris, Jr.

Inventor： Pinaki Panigrahi ,  Ira H. Gewolb ,  J. Glenn Morris, Jr.

IPC: A61K35/74 ,  A61K35/747 ,  A01N63/00 ,  C12N1/00 ,  C12N1/20

CPC classification number: C12R1/225 ,  A61K35/747 ,  C12R1/25 ,  Y10S435/853 ,  Y10S435/857

Abstract: Gastrointestinal tissue injury and infections are treated by orally administering Lactobacilli strains. The Lactobacilli strains prevent neonatal necrotizing enterocolitis tissue injury and necrotizing enterocolitis in preterm infants. Preterm infants, full-term infants, children and adults as well as animals may be given the Lactobacilli strains. The strains are Lactobacillus salivarius strain ATCC 202196 and Lactobacillus plantarum strain ATCC 202195. Further, the strains may be given individually or as a combination of the two strains. In addition, the strains are useful in treating diarrhea. The Lactobacilli strains normalize and balance bacterial milieu in the gastro-intestinal tract. The Lactobacilli strains may be in lyophilized capsule form. The capsule may be an enteric coated slow-release microcapsule. The Lactobacilli strains may also be administered by means of a naso-gastric tube, especially for preterm infants.

Abstract translation: 胃肠道组织损伤和感染通过口服施用乳杆菌菌株进行治疗。 乳杆菌菌株预防早产儿新生儿坏死性小肠结肠炎组织损伤和坏死性小肠结肠炎。 早产儿，足月婴儿，儿童和成年人以及动物可能会获得乳杆菌菌株。 菌株是唾液乳杆菌菌株ATCC 202196和植物乳杆菌菌株ATCC 202195.此外，菌株可以单独给予或作为两种菌株的组合给予。 此外，该菌株可用于治疗腹泻。 乳杆菌菌株使胃肠道中的细菌环境正常化和平衡。 乳杆菌菌株可以是冻干胶囊形式。 胶囊可以是肠溶包衣缓释微胶囊。 乳杆菌菌株也可以通过鼻胃管，特别是早产儿来施用。